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Cardiovascular diseases, including myocardial infarction (MI) and stroke, most often occur on the background of
atherosclerosis, a condition attributed to the interactions between multiple genetic and environmental risk factors.
We recently reported a linkage and association study of MI and stroke that yielded a genetic variant, HapA, in
the gene encoding 5-lipoxygenase–activating protein (ALOX5AP), that associates with both diseases in Iceland. We
also described another ALOX5AP variant, HapB, that associates with MI in England. To further assess the con-
tribution of the ALOX5AP variants to cardiovascular diseases in a population outside Iceland, we genotyped seven
single-nucleotide polymorphisms that define both HapA and HapB from 450 patients with ischemic stroke and
710 controls from Aberdeenshire, Scotland. The Icelandic at-risk haplotype, HapA, had significantly greater fre-
quency in Scottish patients than in controls. The carrier frequency in patients and controls was 33.4% and 26.4%,
respectively, which resulted in a relative risk of 1.36, under the assumption of a multiplicative model ( ).P p .007
We did not detect association between HapB and ischemic stroke in the Scottish cohort. However, we observed
that HapB was overrepresented in male patients. This replication of haplotype association with stroke in a population
outside Iceland further supports a role for ALOX5AP in cardiovascular diseases.
Cardiovascular diseases (CVDs), such as coronary heart
disease and stroke, are major causes of death and dis-
ability in western societies (Aboderin et al. 2002). As a
result of the increasing age of the population, the preva-
lence of CVD is rising worldwide (American Heart As-
sociation 2002). CVDs are largely attributed to athero-
sclerosis, which has various environmental and genetic
risk factors. It is a commonly held view that chronic in-
flammation initiates and promotes the development of
atherosclerotic lesions (Lusis 2000; Libby 2002). Large
epidemiologic studies have demonstrated correlations be-
tween increased production of markers of systemic in-
flammation and future cardiovascular events, including
myocardial infarction (MI) (Ridker et al. 1997, 1998;
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Danesh et al. 2000) and stroke (Di Napoli et al. 2001),
which supports a central role for inflammation in CVD.
We recently published the association of a variant in
the gene encoding 5-lipoxygenase–activating protein
(ALOX5AP [MIM 603700]) with both MI and stroke
in an Icelandic population (Helgadottir et al. 2004).
ALOX5AP, which encodes an important component of
the leukotriene pathway, was identified through a ge-
nomewide linkage scan conducted on 296 families with
MI and subsequent analysis that determined association
with markers within the mapped region on chromosome
13q12-13. A haplotype spanning ALOX5AP, HapA, de-
fined by four SNPs, was shown to be associated with MI
(relative ; ) and, subsequently,risk p 1.8 P p .0000023
the same variant was found to confer risk of stroke in
Iceland (relative risk ; ) (Helga-[RR] p 1.7 P p .000095
dottir et al. 2004). Another SNP-based haplotype within
ALOX5AP, HapB, showed significant association with
MI in British cohorts from Leicester and Sheffield
( ; ) (Helgadottir et al. 2004). WeRR p 2.0 P p .00037
further demonstrated that leukotriene B4 (LTB4) syn-
thesis by neutrophils from patients with a history of MI
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Table 1
Clinical Characteristics of Scottish Patients
and Control Individuals
Characteristics
Patients
( )n p 450
Controls
( )n p 710
Female:male 42:58 49:51
Age (years) 66.8.6 67.2.4
Hypertension (%) 55.5 23.9
Diabetes (%) 12.6 2.1
Total cholesterol (mmol/liter) 5.65.06 5.64.05
NOTE.—Patients and control individuals were classified
as having hypertension and/or diabetes on the basis of
previous history or receipt of antihypertensive or anti-
diabetic therapy. Values with plus-minus symbol () are
meanSE.
is greater than the synthesis by those from controls with-
out MI (Helgadottir et al. 2004).
In the present study, we attempted to replicate the
association of ALOX5AP with stroke in a population
outside Iceland. The SNPs defining HapA (SG13S25,
SG13S114, SG13S89, and SG13S32) and HapB
(SG13S377, SG13S114, SG13S41, and SG13S35) were
genotyped for 450 Scottish patients who had experienced
a stroke and for 710 controls. The patient and control
cohorts have been described elsewhere (MacLeod et al.
1999; Meiklejohn et al. 2001; Duthie et al. 2002; Whal-
ley et al. 2004). In brief, 450 patients from northeastern
Scotland with CT confirmation of ischemic stroke (in-
cluding 26 patients with transient ischemic attack [TIA])
were recruited between 1997 and 1999, within 1 wk of
admission to the Acute Stroke Unit at Aberdeen Royal
Infirmary. Patients were further subclassified in accor-
dance with the TOAST (Trial of Org 10172 in Acute
Stroke Treatment) research criteria (Adams et al. 1993).
Of the patients, 155 (34.4%) had large-vessel stroke, 96
(21.3%) had cardiogenic stroke, and 109 (24.2%) had
small-vessel stroke; for 5 (1.1%) of the patients, stroke
with other determined etiology was diagnosed, 7 (1.6%)
had more than one etiology, and 78 (17.3%) had un-
known cause of stroke despite extensive evaluation. A
total of 710 control individuals with no history of stroke
or TIA were recruited during follow-up of the 1921
( ) and 1936 ( ) Aberdeen Birth Cohortn p 227 n p 371
Studies originally recruited in 1932 and 1947, respec-
tively, as part of the Scottish mental surveys (Deary et
al. 2004). A further 112 controls were recruited from
local primary-care practices (Meiklejohn et al. 2001).
Basic clinical characteristics of patients and control in-
dividuals are shown in table 1. Approval for the study
was granted by the local research ethics committee, and
all study participants gave written informed consent.
The haplotype analysis was performed using the pro-
gram NEMO (Gretarsdottir et al. 2003). NEMO handles
missing genotypes and uncertainty with phase through a
likelihood procedure, by use of the expectation-maxi-
mization algorithm as a computational tool to estimate
haplotype frequencies. Since we were testing only two
haplotypes, which had been shown elsewhere to confer
risk of MI and stroke in an Icelandic cohort and MI in
an English cohort, the reported P values are one sided.
For the at-risk haplotypes, we calculated RR and popu-
lation-attributable risk (PAR) under the assumption of
a multiplicative model (Falk and Rubinstein 1987; Ter-
williger and Ott 1992) in which the risk of the two alleles
of haplotypes a person carries multiplies.
The results of the haplotype-association analysis for
HapA and HapB are shown in table 2. The haplotype
frequencies of HapA in the Scottish populations (patient
and control) were higher than in the corresponding Ice-
landic populations (table 2). As demonstrated in the Ice-
landic population, the estimated frequency of HapA was
significantly greater in Scottish patients who have suf-
fered a stroke than in Scottish controls. The carrier fre-
quency of HapA in Scottish patients and controls was
33.4% and 26.4%, respectively, which resulted in an RR
of 1.36 ( ) and a corresponding PAR of 9.6%.P p .007
We had previously observed in the Icelandic population
a higher frequency of HapA in male than in female pa-
tients with either stroke or MI (Helgadottir et al. 2004).
This sex difference in the frequency of HapA was not
observed in the Scottish population (table 2).
We then tested the association of HapB with stroke
in the Scottish cohort. HapB has been shown elsewhere
to confer risk of MI in an English cohort (Helgadottir
et al. 2004). A slight excess of HapB was observed in
the patient group (6.8%) compared with controls (5.8%),
but it was not significant (table 2). However, sex-specific
analysis showed that the frequency of HapB was higher
in males with ischemic stroke (9.2%) than in controls,
resulting in an RR of 1.65 ( ). The frequency ofP p .016
HapB in females with ischemic stroke was 3.5%, which
was lower but not significantly different from that of
controls. The frequencies of HapB in males and females
with ischemic stroke differed significantly ( ).P p .0021
Interestingly, as shown in table 2, similar trends were
observed in our Icelandic cohort; the frequency of HapB
was greater in males with ischemic stroke (8.6%) than
in females with ischemic stroke (5.8%), although this
was not significant ( ).P p .055
To summarize our results, we demonstrate in the pre-
sent study that HapA, the risk haplotype of ALOX5AP,
reported elsewhere to confer risk of MI and stroke in
an Icelandic cohort, associates with ischemic stroke in
a Scottish cohort. HapB, which confers risk of MI in an
English cohort, was not associated with ischemic stroke
in the Scottish cohort. However, we observed that HapB
was overrepresented in male patients.
Historical and archaeological data have suggested a
Gaelic ancestry for both Icelanders and Scots. This is
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Table 2
Analysis of Association of HapA and HapB with Ischemic Stroke
LOCATION AND STUDY POPULATION (n)
HAPA HAPB
Frequency RR P Frequency RR P
Scotland:
Controls (710) .142 .058
Patients with ischemic stroke (450a): .184 1.36 .007 .068 1.20 NS
Males (253) .183 1.35 .023 .092 1.65 .016
Females (181) .179 1.34 .044 .035 .58 NS
Iceland:
Controls (624) .095 .067
Patients with ischemic stroke (632): .147 1.63 .00013 .073 1.09 NS
Males (335) .155 1.75 .0002 .086 1.31 NS
Females (297) .138 1.51 .0079 .058 .86 NS
NOTE.—Shown are HapA and HapB of ALOX5AP and the corresponding number of individuals
genotyped, the haplotype frequency in the patient and control cohorts, the RR, and the one-sided P
values. HapA is defined by the SNPs SG13S25, SG13S114, SG13S89, and SG13S32, with alleles G,
T, G, and A, respectively, and HapB is defined by the SNPs SG13S377, SG13S114, SG13S41, and
SG13S35, with alleles A, A, A, and G, respectively. For SNP genotyping, we used TaqMan assays
(Applied Biosystems) or the fluorescent-polarization template-directed dye-terminator incorporation
(the SNP-FP-TDI assay), as described elsewhere (Chen et al. 1999). SNP information can be found in
the dbSNP database. The DNA used for the SNP genotyping was the product of whole-genome
amplification, by use of the GenomiPhi Amplification kit (Amersham), of DNA isolated from the
peripheral blood of the Scottish controls and patients with stroke. Data on the Icelandic cohort have
been reported elsewhere (Helgadottir et al. 2004). NS p not significant.
a Sex unknown for 16 patients.
further supported by recent studies of mtDNA and Y-
chromosome diallelic and microsatellite variation in Ice-
landers, Scandinavians, and Gaels from Ireland and Scot-
land (Helgason et al. 2000, 2001). Given this common
ancestry, it is possible that the two populations share a
disease-causing variant and that this variant may reside
on the same common haplotype background (HapA).
Such a scenario would be consistent with our results;
although the estimated RR for HapA in the Scottish
cohort is somewhat lower than in the Icelandic cohort,
this difference is not statistically significant. Indeed, a
similar observation has been made in previous studies
of schizophrenia in Iceland and Scotland (Stefansson et
al. 2003), in which the same extended haplotype was
found to confer risk of schizophrenia in both popula-
tions, with comparable frequencies in patient and con-
trol groups in the two countries.
The gene ALOX5AP encodes the membrane-associ-
ated 5-lipoxygenase–activating protein (FLAP), an impor-
tant mediator of the activity of cellular 5-lipoxygenase
(5-LO), which is a key enzyme in the biosynthesis of
leukotrienes (Dixon et al. 1990; Miller et al. 1990). Leu-
kotrienes are proinflammatory mediators produced pre-
dominantly in inflammatory cells such as polymorpho-
nuclear leukocytes, macrophages, and mast cells. Over
the last decade, a number of studies have supported an
important role for inflammation in atherosclerosis—from
atheroma initiation to promotion of plaque rupture,
thereby triggering thrombosis, the main atherosclerotic
complication that causes MI and stroke (Libby 2002).
The 5-LO pathway could be an important contributor
to the pathophysiology of atherosclerosis through the
formation of the proinflammatory LTB4 and/or through
an increase in vascular permeability caused by cysteinyl
leukotrienes. Indeed, we have shown increased produc-
tion of LTB4 in neutrophils from patients with history
of MI, compared with controls without history of MI
(Helgadottir et al. 2004). This is further supported by
recent human-expression studies (Spanbroek et al. 2003)
that show an increased expression of members of the 5-
LO pathway, including 5-LO and FLAP, in atheroscle-
rotic lesions at various stages of their development.
Moreover, a promoter variant of 5-LO (ALOX5 [MIM
152390]) has been shown to be associated with increased
carotid artery intima-media thickness and with height-
ened inflammatory biomarkers (Dwyer et al. 2004). In
addition, an atherosclerotic mouse model with a hetero-
zygous deficiency of 5-LO shows resistance to athero-
sclerosis (Mehrabian et al. 2002), and an LTB4 receptor
antagonist blocks the development of atherosclerosis in
apoE- and LDLR-deficient mice (Aiello et al. 2002;
Mehrabian et al. 2002). Together, these studies suggest
that chronic upregulation of the leukotriene pathway
may be harmful to the vasculature, in terms of athero-
sclerosis progression and plaque instability.
The precise mechanism by which the ALOX5AP vari-
ants confer risk of MI and stroke is still unclear. As
reported elsewhere, we have not observed SNPs in the
coding sequence that led to amino acid substitution (Hel-
gadottir et al. 2004). Therefore, one can speculate that
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unidentified variation in regulatory regions of the gene—
that affects transcription, splicing, message stability, mes-
sage transport, or translation efficiency—may underlie
the risk conferred by ALOX5AP.
The results of the present study show that HapA as-
sociates with ischemic stroke in a Scottish population,
thereby providing replication of work that showed that
the same haplotype confers increased risk of stroke in
an Icelandic population. This replication constitutes ad-
ditional evidence for the role of ALOX5AP in the patho-
genesis of stroke. Identification of genetic risk factors for
the common forms of stroke may facilitate identification
of individuals at increased risk and may lead to novel
strategies for the prevention and treatment of stroke.
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